Translational Research in Head and Neck Cancer

המעבדה לחקר גידולי ראש צוואר ובסיס גולגולת
Head of the lab:
Dr. Dan Yaniv M.D and Prof. Gideon Bachar M.D.
Lab Manager:
Dr. Elad Hikri, PhD
Phone: 972-3-9376625
Research team:
    Dr. Odeya Abergel Marciano, PhD    
Research Areas:

The Center for translational research in head and neck cancer and skull-base tumors at Rabin Medical Center aims to promote the treatment therapy and improve the quality of life of patients through basic and translational research.

The laboratory practices a "personalized medicine" approach that includes genetic characterization of tumors and optimization of treatment, while reducing side effects.

The laboratory has a tissue biobank, which is the basis for performing studies both in tissue cultures as well as animal models in order to understand the genetics and biology of these tumors and their resistance mechanisms to radiation and chemotherapy. Furthermore, we explore different strategies to overcome these mechanisms and try to develop new therapeutic approaches with the potential to advance to clinical trials. In addition, we conducted studies to explore the role of the immune system in head and neck and skull base tumors by integrating immunotherapy.

Another aspect of research in the lab is the mechanism of treatment-related side effects and their long-term implications in cancer survivors, including radiation and chemotherapy. We aim is to develop methods for preventing or reducing these phenomena and improve patients' quality of life.

The laboratory is located at the Felsenstein Medical Research Center (room 100) and is affiliated with Otorhinolaryngology department at the Beilinson Hospital and Tel Aviv University and works in collaboration with the Head and Neck Oncology Unit at the Davidoff Center for Cancer Treatment and Research.

The leading research projects in the lab are:

  1. Artificial intelligence-driven design of bio-materials and drugs for significant performance improvement, contraindication, and customized medical applications.
  2. Overcoming acquired resistance to PI3K pathway inhibitors in head and neck squamous cell carcinoma.
  3. Characterization of the mechanism of vascular damage caused as a result of chemotherapy treatments and its prevention.
  4. Activation and inhibition of the opiates receptor and the effect on response to treatment in head and neck squamous cell carcinoma.
  5. Radiation induced salivary gland injury; understanding the mechanism and exploring ways to mitigate the effect.
  6. Osteoradionecrosis (ORN) of the jaws, which is the most serious side effect of radiotherapy.
Contact details
Dr. Elad Hikri, PhD Lab Phone: 972-9376625
To contact Translational Research in Head and Neck Cancer, leave your details here: